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O  presente relatório visa apresentar as atividades desenvolvidas  
durante um estágio curricular de 9 meses na Agência de Regulação e 
Supervisão dos Produtos Farmacêuticos e Alimentares (ARFA).  
O objectivo deste estágio na Direção de Regulação Farmacêutica da ARFA foi  
colocar em prática os conhecimentos e competências adquiridas durante o  
primeiro ano do mestrado. A gestão do projeto do Sistema Nacional de 
Farmacovigilância foi uma das principais atividades desenvolvidas durante o 
estágio. Ademais, tive a oportunidade de experimentar outras áreas de 
intervenção da agência, que foram também bastante enriquecedoras. Este 
estágio proporcionou uma visão clara e abrangente de como funciona o sector 
farmacêutico em Cabo Verde, bem como das limitações da farmacovigilância 
em países em desenvolvimento, como o caso de Cabo Verde.  
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abstract 
 
This report intends to present the activities developed during 9-month 
internship at the Agency for Regulation and Supervision of Pharmaceuticals 
and Food (ARFA). The objective of the internship at the Direction of 
Pharmaceutical Regulation of ARFA was to put into practice the knowledge and 
skills acquired during the first year of the masters’degree. The management of 
the project of the National Pharmacovigilance System was one of the main 
activity developed in the direction. Moreover,  the opportunity to experience 
other area of the agency was possible and equally enriching. This internship 
provided a clear and comprehensive view of how the pharmaceutical sector 
works in Cape Verde, as well as the limitations of pharmacovigilance in 
developing countries, as the case of Cape Verde. 
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Introduction 
 
Within the scope of the Master in Pharmaceutical Biomedicine, I enrolled in an internship 
from September 2012 to June 2013. This internship was held in the pharmaceutical 
directorate of ARFA, in Cape Verde, during the second year of my master degree.  
The main purpose was to allow a closed contact with pharmaceutical environment in order 
to apply and complement the theoretical background attained during the first year of my 
master degree; to gain practical knowledge through the application of the attained skills 
and with the experience of senior professionals and to understand the multidisciplinary 
framework of a national medicines regulatory authority (NMRA), especially at the 
pharmacovigilance field.  
The first weeks of the curricular training comprised the basic introduction to ARFA in 
terms of how it is organized, applicable laws and its main role in the pharmaceutical 
environment.  
The internship was then divided in two main components:  
 Permanent Management of the pharmacovigilance system; 
 Training and experimentation of other areas of the agency; 
This report describes my working experience during the internship, starting by providing 
the general knowledge associated to pharmacovigilance and characterizing ARFA and its 
role in the pharmaceutical environment in Cape Verde, and also by reporting all activities 
performed there. So, it is divided in 5 chapters, defined as:  
 State of the art: this chapter starts by providing the general knowledge associated 
to pharmacovigilance and also the current state of the pharmacovigilance in Africa. 
 Host Organization Characterization: this chapter starts by providing a brief 
overview of the health and the pharmaceutical environment in Cape Verde, 
followed by a portrayal of the host organization. 
 Activities Description: this chapter describes the main and the multidisciplinary 
activities performed at ARFA. 
 Discussion: this chapter discusses the main gains achieved during this internship, 
the main difficulties encountered, as well as the general limitation of 
pharmacovigilance in Cape Verde. 
 Conclusion: this chapter gives an overview of my internship experience 
highlighting the importance of strengthening pharmacovigilance in Cape Verde. 
 2 
 
1. State of art 
Over the past few years, medicines have changed the way in which diseases are 
managed and controlled and, the world has achieved major progresses in their health 
status(1). The increase in the worldwide life expectancy and the improvement in the 
quality of life of many people by preventing diseases, reducing disability and slowing 
disease progression are some of the benefits achieved with medicines(2). However, 
despite these positive effects, medicines are not free of risks and harmful effects resulting 
from their use are also known to be as old as medicine itself. Nonetheless, the medicine 
safety issue was not the primary concern in their use(3).  
The history of pharmacovigilance goes back as much as fifty years ago, and the 
worldwide mark was the thalidomide tragedy in 1961-1962. Thalidomide was approved in 
1957 as a safe and effective hypnotic and anti-emetic, and quickly became the most 
popular medicine to treat nausea and vomiting in early pregnancy. Terribly, few years later 
this medicine proved to be a potent human teratogen by causing phocomelia in 
approximately 10.000 children in countries in which it was broadly used(3-5).  
To address this worldwide tragedy, the World Health Organization (WHO) was requested 
to take an active role in assuring the safety of medicines and, it was in 1963 during the 
16th WHO General Assembly that the pharmacovigilance was officially created. This 
science or activity is associated to the detection, assessment, understanding and 
prevention of adverse effects or any other drug-related problem(3, 4). Thalidomide was 
withdrawn from the market in 1965 however is still used today to treat a wide range of 
medical conditions such as the multiple myeloma, multiple sclerosis and Crohn’s 
disease(3). 
This disaster made the world to realize that the medicine’s safety is as well important as 
its efficacy and, in 1978 the safety issues related to medicines was then globalized, 
strengthened and systematized with the establishment of the WHO programme for 
international drug monitoring(6, 7). The Uppsala Monitoring Centre (UMC) is responsible 
for managing this international programme through the collection, storage and analysis of 
individual case reports of suspected ADR (ICSR) submitted by the National Centres. 
Currently approximately 110 countries make part of this programme as official member 
countries and 33 countries as associate members, including developed, developing and 
under-developed countries(8).  
This need to collect the safety information of medicines during its post-authorization phase 
is mainly because the safety data generated during the clinical trials are not enough to 
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map out all possible adverse effects due to the limitations of the studies such as the(9, 
10): 
 Limited size (no more than 5000 and often as little as 500 volunteers is used which 
is insufficient for the detection of rare adverse effect);  
 Strict eligibility criteria (exclusion of concomitant therapies and diseases);  
 Narrow indications (only the specific disease is studied); 
 Short duration (often no longer than a few weeks); 
Thus, despite the concept of adverse drug reaction (ADR) is not standardized,  the WHO’s 
definition of ADR has been in use for about 30 years, and it widely accepted as “a 
response to a drug that is noxious and unintended and occurs at doses normally used in  
man  for  the  prophylaxis,  diagnosis  or  therapy  of disease,  or  for  modification  of  
physiological  function” (11). In Europe, this concept was adapted last year to include 
noxious and unintended responses that resulted from the use of medicine within and 
outside the terms of the marketing authorization thus including, medication error, misuse, 
abuse and occupational exposure(12).  
ADR is a cross-cutting problem that affects children, teen, adult and seniors.  
Nevertheless the elderly population is considered a special case, since the majorities of 
them are polimedicated and have concurrent medical illnesses, alterations in 
pharmacokinetic and pharmacodynamic parameters(13). Furthermore, polypharmacy can 
exponentially increase the rate of ADRs because patients in 4 or more medications have 
an increased likelihood of drug interactions(14). 
Thus, considered today as a challenge issue in the healthcare, ADRs are deemed to be 
responsible for 3–7% of all hospitalizations and affecting 10-20% of all hospitalized 
patients(13, 15).  Besides, although over 70% of all ADRs are potentially preventable, the 
mortality and morbidity associated to the consumption of medicines represents a serious 
health problem(13).  For example, in the USA ADRs are assigned to be responsible for 
about 106.000 deaths per year and are among the six leading causes of death ahead of 
diabetes and traffic accidents(14). In Europe the scenario is not different and ADRs are 
responsible for approximately 197.000 deaths per year(12).  
Hence, based on this fact ADRs are considered to be a major cause of morbidity and 
mortality in health care. Moreover, ADRs may have a significant impact in the health 
budget especially when both cause or extend hospitalization. The cost associated to 
ADRs is estimated by the increasing in the length of hospitalization because the direct and 
indirect costs resulting from ADRs are difficult to estimate(13).  
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In general, ADRs in hospitalized patient may increase the length of hospitalization from 2-
4 days, which may represent an additional cost of approximately $2500 per patient. In 
some countries this increase in the length of hospitalization may represent an increase of 
15-20% of their healthcare budget(8, 16). For example, in the USA the estimated cost of 
drug-related morbidity and mortality is approximately $136 billion annually, which is more 
than the total cost of cardiovascular or diabetic care. In Europe the total cost associated to 
ADRs is approximately €79 billion annually(12, 14).  
This scenario allows classifying the iatrogenic drug disease as frequent, serious and 
troublingly by its cross-cutting impact on health and economy. So, the pharmacovigilance 
can represent an important tool to continuously assure a positive balance between the risk 
and benefit of medicines and reduce or minimize the cost of ADRs.  
Therefore, to enhance the likelihood of detecting ADRs before and after the medicines 
authorization, pharmacovigilance uses a wide range of tools and processes. The 
spontaneous report and the case reports/ case series are one of the main tools used in 
pharmacovigilance to generate hypothesis, which will later be confirmed through 
epidemiological studies such as cohort/case-control studies and randomized controlled 
trials. In addition, some countries like the United Kingdom and the New Zealand combine 
aspects of spontaneous report with epidemiological studies to generate-confirm 
hypothesis through the prescription event monitoring. Nevertheless, the spontaneous 
report is most widely used in the active surveillance of medicines(3). 
 
1.1  Pharmacovigilance in Africa 
Over the past 10 years pharmacovigilance has seen tremendous growth, and in Africa, for 
example, the number of countries with “good” pharmacovigilance capacity increased from 
5 in 2000 to 23 by the end of 2010. Nevertheless, different reasons and needs have 
conducted the development of pharmacovigilance in different parts of the world. In 
developing countries for example, resource constraints and disease demographics, 
particularly the focus on HIV/AIDS, malaria and tuberculosis, have influenced the growth 
of pharmacovigilance, while demand for greater transparency, accountability and access 
to information has driven pharmacovigilance in the developed world(7).  
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Figure 1: Growth of pharmacovigilance in Africa in 15 years (1995-2010)  
 
Consequently, with increasing access to essential medicines newly introduced as the 
combination therapy of artemisinin-based (ACTs) and antiretrovirals (ARVs), the 
importance of surveillance of drug-related problems, particularly in Africa where 
vulnerable populations are receiving treatment for HIV/AIDS, Tuberculosis and malaria, is 
becoming increasingly evident(17). Currently approximately 31 African countries are 
official members of the WHO-UMC Program and 8 countries are associate members(18).  
This awareness, together with the emphasis on global cooperation, helps to strengthening 
the safety of medicines even in resource-limited countries. However, a study in 55 low- 
and middle-income countries demonstrated that there are important characteristics and 
gaps in those national pharmacovigilance centres in African that can compromise the 
safety monitoring and evaluation of medicines. One of the main features is that most of 
the centres are severely understaffed (2 to 4 staffs) and under-resourced(19). This 
framework is also present in Cape Verde. 
Regarding the impact of ADRs on patient morbidity and hospitalization in Africa, several 
studies have documented, and it is estimated that 4.5 to 8.4 percent of all hospital 
admissions in Africa are related to ADRs, and that 6,3 - 49.5 percent of all hospitalized 
patients develop ADRs(20, 21). Furthermore, it is estimated that 45.5 percent of the 
modification or interruptions in antiretroviral therapy are due to the ADRs. For example, 
HIV-infected patients receiving antiretroviral therapy were more likely to be admitted with 
an ADR than those who are not on antiretroviral therapy (20). 
Therefore, besides the impact of ADRs on morbidity and mortality and the attendant costs 
to health systems, ADRs also have other associated costs in terms of the loss of 
confidence in the health system, economic loss to the pharmaceutical industry, non-
adherence to treatment, and development of drug resistance. The importance of 
pharmacovigilance in African countries and other countries is that, regardless the 
 6 
 
existence of pharmacovigilance system, ADRs continue to occurring however when 
pharmacovigilance system does not exist at all, the size and magnitude of the problem are 
completely unknown. For example, inappropriate uses of medicines abound, preventable 
ADRs occur, cost of health care delivery escalates, unsafe and poor-quality products in 
the supply chain goes completely undetected, and harm or even death can occur from use 
of poor-quality products(17). 
In African and other region of globe spontaneous reporting is the rule. However, currently 
there is a growing interest in Africa to introduce active surveillance of cohorts of patients in 
specific disease programmes, as with Cohort Event Monitoring (CEM). For example, there 
is two programmes, supported by WHO, already under way for ACTs in Nigeria and the 
United Republic of Tanzania(22).  
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2. Host organization characterization 
This chapter describes the pharmaceutical sector in Cape Verde, the host company, its 
purpose and activities.  
 
2.1 Overview of Health System in Cape Verde 
Cape Verde is an archipelago of volcanic origin located on the West African coast, 
compound by 10th islands: Santo Antao, S. Vicente, Santa Luzia, S. Nicolau, Sal, Boa 
Vista; May; Santiago, Fogo and Brava. The archipelago has about 491,875 inhabitants, 
according to the census taken in 2010, of which 50.5% are women. Praia is the capital 
with 1301.602 inhabitants, and is the country's largest city(7).  
In relation to the health system organization, in Cape Verde the National Health System is 
designed to include all public and private entities for quality control, research, import, 
production and marketing of medicines and other products used to provide healthcare. At 
the central level, the system includes the departments and agencies that assist the 
Minister in the formulation of health policy, in the exercise of regulatory functions of the 
system and the evaluation of its performance. The decentralization of the national health 
system is made through the delegacies of health whose district coincides with the county 
or municipality (the basis of the administrative division of the country)(23).  
On providers of health care, the country has two central hospitals, three regional 
hospitals, twenty two health centers, thirty-four health centers, one hundred and 
seventeen basic health units, five centers of reproductive health centers and two mental 
health centers. It should be noted that reproductive health care is provided to all health 
centers. Regarding human resources, in 2011, the physician ratio was 5.7 / 10,000 
inhabitants, 10.4 / 10,000 inhabitants for nurses ratio and 0.4 /10,000 inhabitants for 
pharmacists ratio(24).  
The country is in the transitional phase of the epidemiological profile, where 
noncommunicable disease have been overcome in terms of prevalence and severity 
communicable disease, although acute respiratory infections diseases, diarrheal, 
tuberculosis and HIV/AIDS infection continue to represent a public health problem.  
The average life expectancy at birth in the country, estimated in 2013, is 71.28 years, and 
66 years for hoemens and 71 years for women. In 2013, the estimated mortality rate is 
around 6.22 deaths/1.000 inhabitants, and the birth rate around 20.96 births /1.000 
inhabitants(25).  
 8 
 
 
2.2 Overview of Pharmaceutical Sector in Cape Verde 
The global pharmaceutical environment is undergoing multiple changes at different level, 
with the emergence of new paradigms in the areas of manufacture and treatment, 
particularly with a focus on personalized medicine and advanced therapies. Thus, in this 
global frame, challenges increasingly larger and more complex arise to the NMRA, 
requiring new regulations, guidelines and laws regarding the safety, quality and efficacy of 
new medicinal products.  
In Cape Verde the regulation of the exercise of pharmaceutical activity is installed and 
develops with progression at efficacy and credibility level. From its impact on the public 
heath arise already substantial and evident gains, announcing a future of greater solidity 
and balance of interest to all of those involved. The characteristics of the sector in Cape 
Verde are typical of a market in which parts of the chain are in monopoly, controlled by 
agreements, formal and informal, as regards the form of activities of agents in the market. 
The main players in the value chain are the suppliers, producers, wholesalers and 
retailers.  
With regard to the regulatory bodies, it should be noted that the following main entities are 
involved: the General Directorate of Pharmacy (DGFM) and the Agency for Regulation 
and Supervision of Drugs and Foodstuffs (ARFA). 
The DGFM is a central service of the health minister whose mission is to define, regulate, 
implement and evaluate the National Pharmaceutical Policy (NPP) for the protection of 
public health and assurance of access of health professionals and citizens to medicines 
and health products of quality, safe and effectives. The DGFM is also responsible to 
coordinate and provide technical support to the management of medical devices. Thus, 
among other aspects, the DGFM is responsible to(26): 
 Promote and participate in policy formulation on the production, marketing, import, 
export, re-export control and consumption of medicines and other pharmaceutical 
products; 
 Organize competitions and license industrial and commercial establishments that 
manufacture and marketing medicines and supplies; 
 Maintain update the records of pharmacies, manufacturer, warehouses and the 
National Medicines List (NML); 
 Contribute to the quality assurance of medicines; 
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With the recent approval of the decree-law which establishes the new status of ARFA, the 
competence of DGFM of marketing authorization of medicines, distribution and monitoring 
was revoked, being now, the ARFA the responsible for this competency(27). 
The ARFA is responsible for the exercise of administrative activity of technical and 
economic regulation of the pharmaceutical sector and food. In terms of pharmaceutical 
regulation, the ARFA is responsible for medicine marketing authorization and monitoring 
(competences recently acquired), pricing and stock supervision. These competences will 
be further developed in the next section(27).  
To understand the main agents of the pharmaceutical sector in Cape Verde, it is important 
to primarily understand that the choice of medicines to be imported meets a legal criteria, 
which establish that the International Non-proprietary Name (INN) to be imported must 
belong to the NML in force. Nevertheless, in situations duly provided by law (clinical 
conditions, investigations and clinical trials) medicines can be imported even if the INN 
does not belong to NML in force(28). The NML is the relationship of medicines whose 
market availability is guaranteed by the government, producers and importers(29). The 
update of the NML is ensured by the National Commission of Medicines, an advisory body 
whose members are appointed by the Minister of Health and formalized by publication in 
the Official Gazette. This commission is composed of physicians and pharmacists, 
representing the various players in the sector(26). 
In terms of market operators it should be noted that the following entities are involved: 
 EMPROFAC - Empresa Nacional de Produtos Farmacêuticos, S.A.R.L.; 
Founded in 1979 as a public company, the EMPROFAC has to date a monopoly on the 
import and wholesale distribution of medicines. In 1997 became an anonymous society 
with the status of private company with 100 percent public capital. The EMPROFAC has 
as mission ensuring a regular supply of safe, effective, quality medicines. Currently 65% 
of medicines consumed in the country are imported by EMPROFAC, and the remaining 
acquired through the INPHARMA(30). 
The INN imported by the EMPROFAC must belong to the NML. The purchase of 
pharmaceutical product is done by two methods: 1) annual procurement through 
international competition for products intended to hospital facilities; and 2) Direct 
procurement through suppliers of recognized quality. The requests are made annually 
with the indicative quantities and orders and are made four times a year, which allows to 
adjust the quantities to the current consumption(31). 
 INPHARMA - Indústria Farmacêutica, S.A.R.L.; 
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The INPHARMA  is a Portuguese-Cape Verdean company under private law, created with 
the objective of strengthening the autonomy of the country in the pharmaceutical sector; 
reduce foreign exchange costs; capture technologies and to value the existing human 
resources through the creation of jobs. The INPHARMA covers approximately 36% of 
domestic consumption. The production of medicines is based on generic and brand 
medicines manufacturing under license of other partners (eg. Labesfal and Azevedos). 
Injectable products are not manufactured by require high investments. Besides, due to the 
limitation of the internal market, production is usually limited to products most consumed 
medicines in the country(32). The share of INPHARMA in the medicinal product market 
has grown while remaining at around 36%, mainly due to the model of the pharmaceutical 
sector in Cape Verde. The non-privatization of EMPROFAC, which holds 40% of 
INPHARMA, has been one of the major constraint to the INPHARMA(33). 
In relation to the distribution of the imported products, the private sector is supplied 
directly by the EMPROFAC and accounts for about 60% of the distribution. The public 
sector (health centers) is supplied through the deposits of DGFM: Central (Praia) and 
Regional (Mindelo), who acquire products from the EMPROFAC and INPHARMA. Given 
the autonomy provided to the Central Hospitals ("Agostinho Neto" (Praia) and "Baptista de 
Sousa" (Mindelo)) these facilities can be directly supplied by the EMPROFAC and 
INPHARMA(34)."  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Pharmaceutical Sector in Cape Verde 
 
To understand the pricing system in force in Cape Verde, it is important to emphasize that 
all medicines imported are pre-selected based on INN. In Cape Verde, are subject to the 
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pricing system all existing medicines in the country, with the exception of non-prescription 
medicines, herbal remedies, homeopathic, manipulated and veterinary medicines. The 
medicines excluded from the pricing system are, however, subject to monitoring 
procedures and regulation to be prepared by ARFA(35). 
The medicines are supported by the National Institute of Social Security (INPS), 
Government Budget/Ministry of Health and by consumers. The INPS manages the 
reimbursement system, which covers approximately 25% of the population(34).   
Although the pharmaceutical sector in Cape Verde has undergone major changes in its 
organization and functioning, limited human and financial resources did not allow a full 
evaluation of the medicinal product, mostly imported. The inequality in accessibility to 
medicines is deep, when comparing the situation of the beneficiaries of the INPS with a 
large proportion of the population who do not have the resources to health care expenses. 
All this factors encourages the unregulated supply chain such, street vendors and other 
unlicensed outlet, which may constitute a serious public health problem. 
Furthermore, the limitations in the control system of imported products, which is restricted 
to the WHO certification and certificates of analysis provided by the supplier, and the 
inoperability of the Official Laboratory for Quality Control, only contribute to aggravate this 
scenario. Besides, the inspective ability is also manifestly weak due to lack of technical 
and financial resources. 
2.3 Overview of the Host Organization  
My internship occurred at ARFA, a NMRA, which is situated in Praia, the capital of Cape 
Verde. The ARFA was established in 2004 by Decree-Law (DL) nº 42/2004 of 18 October 
2004 to carry out technical and economic regulation of food and pharmaceutical products. 
The ARFA's mission is to ensure that the population of Cape Verde has access to 
medicines and foods of quality and safe. The ARFA still has the mission to follow the 
market supply of staple foods, especially in proceedings relating to food aid. (36). 
Thus, under the program "State Reform and Public Administration", which aims at 
strengthening citizenship, modernization, transparency and rationalization of structures, 
was recently approved the DL nº 22/2013 of 31 May 2013, which determines the 
incorporation of ARFA with the National Agency for Food Safety (ANSA), by the 
transferring the whole of the duties, powers and legal status, rights and obligations of 
ANSA to ARFA, and approves the new statutes of ARFA. 
The ARFA while independent administrative authority, institutionally based, endowed with 
regulatory functions, including regulation, supervision, pricing and sanctioning of violations 
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enjoys administrative, financial and patrimonial autonomy. The ARFA, in its mission to 
defend the legitimate interests of consumers has in particular the following pharmaceutical 
competencies(27):  
a) Regulation Competences 
 Regulate and supervise activities related to the life cycle of pharmaceuticals 
products and food, aimed at sanitary food safety and quality and the safety and 
efficacy of pharmaceutical products; 
 Regulate the functioning of the national pharmacovigilance system (NPS); 
 Regulate technical requirements applied to production, import, export, distribution 
to ensure food safety and quality, safety, quality and efficacy of pharmaceutical 
products; 
 Establish codes of good practice within their assignments, etc; 
 
b) Supervision Competences  
 Oversee the implementation and enforcement of laws, rules and technical 
requirements for regulated industries as well as the provisions of the respective 
titles of exercise activity; 
 Ensure proper functioning of the market and its transparency, while respecting the 
established rules and standards, avoiding any practice that inhibits competition 
and harmful to the consumers, without prejudice to the powers of the competition 
authority; 
 Supervision of the national supply of medicines subject to the regime of mandatory 
minimum stock as well as staple foods; 
 Ensure and monitor the fulfilment of international obligations under its powers; 
 
c) Pricing Competences 
 Promote the establishment of mechanisms of control and price fixing of medicines 
and the supervision of its compliance; 
d) Sanctioning Competences 
 Prosecute and punish the violations to the laws and administrative regulations 
which it is responsible for implementation and supervision; 
 Collaborate with external supervisory bodies of the state in initiation and 
prosecution of breach proceedings; 
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Thus, despite the vast body of powers conferred to ARFA, the agency's intervention does 
not include veterinary medicines and medical devices(27). 
In organizational terms, the option for this stage favours a structure that is feasible, in light 
of human and financial conditioning that the agency can mobilize (Figure 1). However, the 
adopted structure is based on an evolutionary perspective, able to support developments 
that accumulated experience and external environment may justify. So with the recent 
merger of the agency, the organizational structure approved integrates: 
 Bodies of the direction, supervision and consultation  
 Technical Service  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: ARFA Organigram 
 
To make effective the security in the consumption of pharmaceuticals and foodstuffs, the 
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Market (SIMFAR), with the configuration of a market observatory, which integrates 
economic regulation (drug stock /prices) and the drug post-marketing surveillance system 
(VIGIMED); the Food control System (SNCA) and the Integrated Rapid Alert System of 
Food (SIARA), configured for the detection of non-compliance situations inherent to foods 
that will reduce the risks associated with the consumption of food for human and animal 
consumption(37-39). 
2.3.1 Directorate of Pharmaceutical Regulation  
My internship occurred mainly at the directorate of pharmaceutical regulation (DPR) of 
ARFA. The DPR is the technical direction of the agency, which is responsible for technical 
and economic regulation of the pharmaceutical market, in order to promote the quality and 
safety to the consumers through the regulation and supervision of the activities related to 
the life cycle of pharmaceuticals products(36).  
The responsibility of DPR can be divided in the three main areas of interventions and 
comprise the following competences:  
 
 Regulatory Framework 
 Promote and coordinate the activities of standardization and harmonization of 
concepts, definitions and terminologies related to medicines, cosmetics and 
biocides; 
 Develop and propose draft laws, regulations, standards and requirements 
regarding: 
 The functioning of the national pharmacovigilance; 
 Pricing regime of medicines for human use; 
 Supply and stock management of medicines; 
 Production, import, export, distribution and advertising of medicines 
for human use; 
 Technical requirement to cosmetic products and biocides; 
 
 
 Technical and Economic Evaluation  
 Manage the procedures and activities to ensure quality assurance, safety and 
efficacy required for marketing authorization of medicinal products for human 
use, cosmetics and biocides; 
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 Investigate the impact of international alerts on the national territory and 
propose safety measures; 
 
 Supervision and Market Monitoring  
 Monitor the prices of medicines for human use, and evolution trend of 
medicines market; 
 Monitor the supply and distribution circuit of medicines for human use; 
 Ensure the collection and processing of information on the use of medicines; 
 Ensure the collection of statistical and economic data relating to the medicine 
sector; 
The DRP is headed by the pharmacist, Dr. Eduardo Tavares, who is supported by other 
pharmacists and administrative staff. The direction is constituted by three multifunctional 
technicians. Thus, due to the limited human resources it is important that all directorate’s 
members communicate effectively one with another and work together to maintain the 
agency scientific standards. To facilitate this, all members of the directorate meet on a 
monthly basis to keep one another’s updated on their main activities, new activities 
assignments or other recent important scheduled events. 
The DRP is also responsible for the preparation and communication of any safety alert 
with medicines to the health professionals and market operators. Recently, I was 
responsible to the development of one of the ARFA's publications: the “Obseratório”. This 
is a weekly publication, which aims to create an open line of communication and broader 
collaboration between health professionals and national pharmacovigilance centre. In 
addition, this publication aims to inform health professionals and encourage them to be 
more aware about the events that can occur with the use of medicines and the importance 
of these events in improving the delivery of patient care. 
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3. Activity Description 
3.1 Main Activity – National Pharmacovigilance System  
During my internship I was responsible to “manage” the project of the national 
pharmacovigilance system (NPS), which comprised essentially in the management of the 
reports of suspected ADRs and quality problems received; the communication of any 
safety or quality alert and the sensitization of the health professional about the importance 
of pharmacovigilance in improving the delivery of healthcare to patients.   
Despite the establishment, in 2006, by the DL 59/2006 that the marketing authorization 
holders (MAHs), physicians, technical directors of pharmacies and other health 
professionals should inform DGFM (now ARFA) of all adverse reactions that have 
knowledge, this legal requirement was not enough to awaken the responsibility in many of 
these professionals(28). Thus, to establish and define the main responsibilities of all key 
players in the pharmaceutical system, there is currently a proposal of a DL for the 
establishment of national pharmacovigilance system (NPS). This DL aims to define the 
rules of organization and functioning of this system, which is mainly based on the 
spontaneous reporting of ADRs and quality problems. 
3.1.1 The project of the National Pharmacovigilance System  
In Cape Verde, the diagnosis of pharmaceuticals sector produced under the NPP in 2003 
identifies weaknesses in the medicines marketing authorization system, to which is added 
the large deficits in the monitoring of medicines during post-marketing. Thus, this 
instrument foresees in the field of pharmacovigilance "the establishment of a system for 
collecting and analysing data on adverse and toxic reactions arising from the use of 
medicines”(34). In line with the provisions in NPP appears in the DL nº 59/2006, which 
regulates the marketing authorization of medicines for human use, the determination that 
“the DGFM while the pharmacovigilance system is not configured should receive reports 
of ADRs, analyse those information and propose measures deemed appropriate to protect 
public health”(28). 
Nevertheless, with the competencies of market monitoring of medicines and 
pharmaceuticals assigned also to ARFA in the old status, the agency promoted the design 
of an integrated monitoring system - SIMFAR, supported by an information system that 
enables the implementation of a broad model of pharmacovigilance enabling timely 
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collection and processing of reports and management of signs and risk, both in terms of 
safety as in relation to quality problems which includes counterfeit medicines. 
To this end, were initiated a series of meetings that had as its main objectives: the 
identification of shortcomings and their impact on the various players of the 
pharmaceutical sector; the discussion of the model more adequated to the current reality, 
as well as the awareness of the players to the importance of pharmacovigilance. Thus, of 
the recommendations worth mentioning the need and the urgency in the implementation 
of the pharmacovigilance system; the need to prepare a draft of the DL for the 
pharmacovigilance system, and the implementation of the decentralized scenario (with 
various national representations) as the most feasible for the pharmacovigilance system in 
Cape Verde. 
Thus, of the decision to create the pharmacovigilance system in Cape Verde comes the 
option to start the process of preparing for integrating in the international program of drug 
monitoring, whose management is entrusted to the UMC. Nevertheless, Cape Verde 
should prepare and implement a plan of activities to comply with the minimum 
requirements set by the WHO. Hence, to this end, the ARFA promoted, along the Ministry 
of Health, the stage of awareness and advocacy for it to be designated as the authority to 
receive the functioning of the national centre of pharmacovigilance, and from the formal 
indication of ARFA as the national centre of pharmacovigilance, it was agreed with the 
UMC a work plan whose objectives included: 
 Develop and implement a reporting system; 
 Sensitize the health professionals about the importance of pharmacovigilance; 
 Prepare for patients reporting; 
 Establish a national commission of pharmacovigilance; 
 Prepare for the transition from associate member to official member of the UMC 
international program; 
 Submit to government approval the project of the NPS; 
Of the realization of training in pharmacovigilance and the sensitization of the 
pharmacovigilance to the key players of the system, it is elaborated the proposal of the DL 
that institutes the NPS. The proposal predict a networking of various players such as 
authorities, inspection services, universities, public health institutions and other health 
professionals, which will be mainly based on spontaneous reporting of suspected ADRs 
and quality problems made by health professionals and patients. Thus, the NPS has as 
main objectives: 
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 Determine the methodologies for the collection, processing and dissemination of 
information on quality and safety of medicines; 
 Identify and collect systematically suspected ADR's to medicines, quality problems 
and other issues related to the drug use; 
 Analyse and evaluate the information collected on time, using support information 
systems and procedures; 
 Identify signs and establish procedures for management and communication, in 
order to minimize the risks and maximize the benefits from the use of medicines; 
 Systematically assess the profile of quality and safety of medicines used in the 
country; including the relationship between benefit and risk of medicines; 
 Promoting rational use of medicines; 
 Promote knowledge in pharmacovigilance; 
The structure of the NPS integrates the following entities: 
 Central Organ of the NPS 
The Central Organ of the NPS is the national pharmacovigilance centre that works in 
ARFA, and is responsible for management and supervision of this system, adopting 
standards and technical guidelines that the pharmacovigilance activities must comply. 
 Risk Management Centres of regional or local scope 
Public health institutions that assume the role to collect validate and send reports of 
suspected ADR's and quality problems to the central organ of the NPS. 
 Delegates of pharmacovigilance (when appropriate) 
Health professionals both within and outside the National Health System (NHS) who are 
responsible for collecting reports of suspected ADR's and quality problems, and 
collaborate with the central organ of the NPS both in obtaining additional information for 
analysis and evaluation, and in the dissemination of safety measures decided by this 
body. 
 MAH and Economic Operators  
Establish pharmacovigilance procedures and nominate the technician in charge; collect 
and submit reports of suspected ADR's and quality problems to the central organ of the 
NPS; collaborate with the central organ of the NPS in the implementation of safety 
measures and assist in the dissemination of these. 
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 Health professionals  
Professionals authorized to prescribe, dispense, and administer medications, or provide 
health care inside and outside the NHS, should communicate as soon as possible, to the 
central organ of the NPS, the risk management centre or the delegated of 
pharmacovigilance suspected ADR's or quality problems that have knowledge. 
 Health Educational Institutions and Consumer Representatives 
Constitute partners in the education of patients and the general public and in raising 
awareness about issues related to the safety and quality of medicines. 
 Pharmacovigilance Commission 
Constitute the advisory body of the NPS in pharmacovigilance issues, providing technical 
and scientific opinions relevant to the safety and quality of medicines, thereby 
contributing, to informed decisions by the central organ of the NPS. The competences of 
the pharmacovigilance commission include:  
i. Assist scientifically and technically the NPS; 
ii. Technical-scientific opinions; 
iii. Prepare and approve its laws, and more submitted to it ; 
The pharmacovigilance Commission will be constituted by a representative of the central 
organ of the NPS; a representative of DGFM; a representative of the National Health 
direction and a representative of the risk management centre. This proposal has already 
been submitted for government approval. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: The NPS network 
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3.1.2 Spontaneous Reporting System  
The main activity performed during this internship was to manage the reports of suspected 
of ADRs and quality problems.  
In Cape Verde, the project of the NPS begins to receive its first reports in 2010, and since 
then the system relies on the spontaneous reports.  
Spontaneous reporting is generally understood as an unsolicited communication by health 
care professionals or consumers that describes one or more suspected adverse events in 
a patient who was given one or more medicinal products and that does not derive from a 
study or any organized data collection scheme(40). The SRS plays a key role in the early 
detection of signals, allowing the generation of hypotheses concerning the possible 
adverse effects associated to the use of medicines. The added value of this system lies in 
that it allows experienced professionals in medicine safety monitoring to select reports 
that indicate the beginning of a serious ADR or one not detected earlier. Thus, the 
spontaneous report allows: early detection of ADR not yet identified; identification of risk 
groups; obtaining reliable estimates of toxicity compared between medicines within the 
same therapeutic class and continuous monitoring of safety data. Besides, it allows a 
monitoring on a large scale, covers the whole life cycle of the product and does not 
interfere with the prescribing habits(41).  
Nevertheless, such as with other methods the SRS has important limitations to consider in 
the use of information from reports. Among the limitations import to highlight:(9) 
 The recognition of the adverse effect 
This recognition is subjective and imprecise, and although it is always assumed the 
existence of a causal relationship between the observed effect and the suspected 
medicine, all efforts are developed to exclude other possible explanation for the case.  
 The underreporting 
This is the major limitation of SRS. It is estimated that only 10% of all adverse reactions 
are reported(42).  
 The bias 
Unlike what happens with the data obtained in clinical trials, information resulting from 
spontaneous reporting is not controlled, being thus subject to the possible influence of 
several confounding factors.  
 The quality of reporting 
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The ability to analyse the reports depends on the quality of information in the report made 
by health professionals. 
In Cape Verde, the reports of suspected ADRs are accepted from health professionals, 
MAHs and patients (although they are not aware of that they can report). The reports can 
be sent by mail, fax or telephone, being on any means guaranteed the confidentiality of 
data in relation to the patient and the reporter(43). The reporting forms are designed to 
enable the collection of ADRs and quality problems related to medicinal product, and 
consist basically in eight topics, where four are considered mandatory. The eight topics 
comprise: the 1) identification of the patient, i.e., it’s important to have an identified and 
identifiable patient; 2) the identification of the suspect product, which can include vaccine 
and other medicinal products; 3) the identification of concomitant medication 4) the 
description of the ADR or the quality problem; 5) the evaluation of the seriousness of the 
problem; 6) the evolution of the problem, i.e., in case of ADR, the patient’s evolution in 
relation to the ADR; 7) the reports comments, where can be included medical history, drug 
allergy or other patient’s habits that can have impact on the evaluation of the case; and 
last the 8) identification of the reporter. The current reporting form is identified below.   
During this internship, one of the first activities that I have been proposed was to develop 
a new reporting form and abbreviated one (Appendix 1) since there was some missing 
information and how the information is requested does not allow much information to be 
gathered. For example, in the field "treatment of reaction," the idea of leaving the field 
blank to be filled by the profisisonal has not allowed that much information be obtained, 
and in a scenario in which the reporter had several options regarding the intervention 
made in relation to the suspected medicine, it would be more easy to obtain more 
information.  
It lasted about one week to propose a new reporting form and an abbreviated one. For the 
abbreviated, the information considered essential were maintained and includes the 
information about the patients, the suspect product, the description of the problem and the 
reporter identification. At the end of the report form there is a clause that alert the health 
professional for the needs to provide more information of the case to the ARFA. 
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Figure 5: The current report Form 
Nº do processo precedente______
1. Identificação do doente
*Dosagem *Fabricante Lote Validade
Dosagem Fabricante Lote Validade
Notificação nº:___________________
Telefone:
Email:
Instituição:
Notificação de seguimento?_______
Os campos assinalados com (*) são de preenchimento obrigatório
7. Comentários Adicionais (ex. histórico de saúde; alergias; exames médicos; etc.)
    Em Recuperação 
Sequelas: Sim       Não         Descrição da(s) sequela(s) _____________________________________________________
Hospitalização prolongada 
CENTRO NACIONAL DE FARMACOVIGILÂNCIA
CONFIDENCIAL
Formulário de Notificação de Suspeitas de Reações Adversas e/ou Problemas 
Relacionados com Medicamentos
    Desconhecido
4. *Descrição da Reação adversa ou problemas de qualidade                        *Data de inicio da reação: ____/____/_____
Tratamento da reação:
    Recuperou, data____/____/_______ 
Assinatura:
Obrigado pela sua colaboração em notificar!
Endereço:
Data da Notificação: ___/____/______
Móvel:
8. *Dados do Notificador
Risco de vidaMorte
___/___/_________/___/______
*Data de nascimento ou idade:
___/___/______
*Inicio de uso
5. Gravidade
___/___/______
*Fim de uso
Fim de usoMedicamento
___/___/_____
___/___/______
2. *Medicamento/ Vacina Suspeito (a)
3. Medicamentos concomitantes
*Sexo: F      M
Peso:___________Kg
Inicio de uso
*Nome ou iniciais: 
ContactosNome: Profissão:
6.Evolução
*Medicamento Razões de uso
___/___/______
___/___/______
Outro    Assistência médica
___/___/______
Razões de uso
___/___/______
___/___/______
___/___/______
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The ADR reports are processed by the technician responsible for pharmacovigilance in 
ARFA, which during the internship was under my responsibility. The reports are 
processed using a method that involves three sequential steps comprising (Figure 6): 
1. Reception and validation of reports; 
2. Analysis and insertion on the database; 
3. Feedback to the reporter; 
 
 
Figure 6: The Current Structure of the SRS  
 
1. Reception and validation  
A reporting of ADRs is related to a single case, where there is an identifiable patient and 
reporter, at least one suspected ADRs and at least one suspected drug. These are the 
minimum information required for the report to be inserted in the VigiFlow database, since 
the SIMFAR database is not working.  For the reports to be considered valid it is required 
to contain the minimum information referred above. However, for any reports that do not 
present the minimum criteria, regardless if it is serious or unexpected, procedures are 
triggered to get immediately all the information needed from the reporter or other source 
available. If the initial reports are made orally or by telephone, procedures are triggered to 
obtain written confirmation by a health professional. The validation process consists 
essentially of data quality control. 
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2. Analysis and Insertion on the Database  
The evaluation of each reports corresponds to the validation of information, determination 
of seriousness, predictability and performance of the procedure for imputation of causality, 
i.e., analyse whether the minimum criteria are present, if the reaction is serious or not, 
expected or unexpected and determine what is the probability of a causal relationship 
between the suspected ADR(s) and the suspect product, analysing also possible 
medicines interactions. 
Since it essential to ensure that there is no misunderstanding in the data reported and to 
clarify questions about the verbatim it resorts to the latest versions of terminologies such 
as the WHO Drug Dictionary and WHO Adverse Reactions Terminology (WHO-ART) or 
Medical Dictionary for Regulatory Activities (MedDRA). The data collected in this phase 
and then entried in the database and coding can be used to future evaluation of any 
safety measures.  
The seriousness of the adverse reaction is classified taking into account the judgment of 
the reporter, and when it does not provide, the classification is made considering the List 
of Adverse Event / Reaction Terms to be Considered Always "Serious" published in 
Current Challenges in Pharmacovigilance: Pragmatic Approaches - Report of CIOMS 
Working Group V, Geneve, 2001, which is based on the WHO Critical Terms List. 
The classification of an adverse reaction as "expected" or "unexpected" is taken by 
resource to the Summary of Product Characteristics (SPC), and when the nature, intensity 
and evolution of the ADR reported does not differs from those described in the SPC, the 
reaction is classified as expected.  
In terms of causality assessment, in Cape Verde all reports of ADRs received are 
assessed in terms of causality imputation. The causality assessment is part of the 
diagnostic process of ADR, which establish the relationship between a drug and a 
suspected reaction. The difficulty is to determine if a specific clinical condition was 
induced by a drug or not, since in practice, few adverse reactions are "certain" or 
"unlikely;" most are somewhere in between these extremes, i.e., "possible" or "probable." 
So, in the attempt to solve this problem, a variety of methods are used for causality 
assessment, each with its own advantages and limitations. These methods include:  
 Global Introspection: causality inference obtained via clinical judgment, such as 
with an expert panel. This method is the most common approach for individual 
causality assessment of adverse drug reports. However the process of global 
introspection is known to be subjective, and despite its usefulness, the global 
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introspection method has been subject to criticisms of subjectivity, imprecision, and 
poor reproducibility because it is mainly based on expert clinical judgments. 
 Algorithms: sets of specific questions with associated scores for calculating the 
likelihood of a cause-effect relationship. The use of a standardized instrument was 
intended to lead to a reliable and reproducible measurement of causality, in a 
structured way. There are several decision support algorithms available to make an 
explicit and reproducible assessment of causality. However, there is no universal 
algorithm, scoring can be arbitrary and responses to questions can be subjective.  
 Bayesian approaches: express the relationship between the probability of a 
proposition before (prior estimate) and after the acquisition of the data (posterior 
estimate).  
The three methods of causality assessments while different share common factors for 
consideration: the temporal relationship; dose relationship; de-challenge/re-challenge; 
recognized association with the product/class; pharmacological plausibility; underlying 
illness/concurrent conditions and other medications. 
A variety of algorithms have been developed over these years, and some examples of 
algorithms/scales used include: WHO assessment scale; Karch and Lasagna’s scale; 
Naranjo’s scale; Kramer scale; Yale logarithm; European ABO system and the Spanish 
imputation system. The algorithm of Naranjo, Karch & Lasagna, and scale evaluation of 
the WHO are the most commonly used. In Cape Verde, the causality assessment 
methods used to analyze the reports are the algorithm approach (Naranjo’s scale). 
The algorithm of Karch & Lasagna consists of a number of closed questions to be 
answered in a dichotomous way. The combination of the results leads to the 
establishment of the "strength" of the causal relationship. However, although the method 
give objectivity to the diagnosis, it is useless to identify unknown reactions. Moreover, it 
does not provides criteria for individuals judgments or data for reproducibility evaluation, 
and an ADR can only be judged if there was re-exposure of the drug, which is rarely the 
case(44). 
The Naranjo algorithm, or Adverse Drug Reaction Probability Scale, is a method of 
causality imputation by which it is assessed whether there is a causal relationship 
between an identified untoward adverse event and a drug by using a simple questionnaire 
to assign probability scores. This method consists of 10 questions that are answered as 
either Yes, No, or “Do not know”, in which different point values (-1, 0, +1 or +2) are 
assigned to each answer. At the end a causality assessment is made by calculating the 
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number of points, and depending on the point score, the strength of a causal relationship 
is then considered such as definite, probable, possible or unlikely”.  
A simplified version of the 10 questions is provided in the table below(45). 
Question Yes  No Do not 
know 
Are there previous conclusive reports on this reaction?  +1   0 0 
Did the adverse event appear after the suspected drug was 
administered? 
 +2 -1 0 
Did the adverse reaction improve when the drug was discontinued or 
a specific antagonist was administered? 
+1 0 0 
Did the adverse reaction reappear when the drug was re-
administered? 
 +2 -1 0 
Are there alternative causes (other than the drug) that could solely 
have caused the reaction? 
 -1 +2 0 
Was the drug detected in the blood (or other fluids) in a concentration 
known to be toxic? 
 +1 0 0 
Was the reaction more severe when the dose was increased or less 
severe when the dose was decreased? 
 +1 0 0 
Did the patient have a similar reaction to the same or similar 
medicines in any previous exposure? 
 +1 0 0 
Was the adverse event confirmed by objective evidence?  +1 0 0 
Total score       
Total score categories are defined as follows: 
ADR is: certain > 9; probable 5-8; possible 1-4; unlikely 0. 
 
Table 1: Naranjo algorithm for assessing the causality of an ADR 
 
Despite these limitations, these do not invalidate the proposed algorithms and their 
application within routine situations has been an important tool for the diagnosis and 
treatment of ADRs. Thus, considering the existence of limited human resources, the 
Naranjo’s algorithm was chosen because it’s less complex and less time consuming(46).   
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Thus, given the ineffectiveness of the SIMFAR database, the reports of ADRs are 
introduced since June 2011 in the VigiFlow database, in consequence of the integration of 
Cape Verde as member of the UMC.  
The VigiFlow is an ICSR management system developed and hosted by UMC that is 
specially designed for use by national centers in the WHO programme for international 
drug monitoring. It is compatible with the ICH-E2B standard for electronic transmission of 
ICSRs. The ICSR data can be manually entered into VigiFlow with support from the 
terminologies such as the WHO Drug Dictionary and WHO-ART or MedDRA.  
In the filling of the "report form" there are mandatory fields that must be completed for the 
case to be considered valid by the UMC and a built-in error check, which help the users to 
add data correctly. It is also possible to import ICSR data as XML files in the E2B format. 
In countries with several regional pharmacovigilance centers the access to the VigiFlow 
can be tailored to the respective rights(47). However, in Cape Verde there is one 
pharmacovigilance center, which is hosted at ARFA - the national pharmacovigilance 
center. There are several characteristics that make VigiFlow friendly to countries with 
limited resource as the case of Cape Verde, and such characteristics include (48): 
 Handling of ICSRs 
The possibility to add a digital "post-it" note to the ICSR makes communication easy in the 
VigiFlow. Once the report is complete and committed the first version of the ICSR is 
considered to be finalized. It is easy to retrieve reports to amend the contents or add 
follow-up information. 
 Analysis 
The availability of a search and statistics module in the VigiFlow makes easy to analyze 
the ICSR already inserted. The results can be exported in different output formats, either 
as PDF files or in spreadsheet format compatible with Microsoft Excel. 
 Communication with External Organizations 
The ICSR data can be sent to external contacts such as companies or other regulatory 
agencies either as PDF files (as computer files or hardcopy printouts) or in E2B formatted 
XML files.  
 Technical Information 
Since VigiFlow works over the internet, no local installations, back-ups or maintenance 
are necessary. The only requirements are a web browser, preferably Mozilla Firefox or 
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Internet Explorer, and an internet connection. The internet access is encrypted and any 
information stored in VigiFlow is only accessible by users within the same 
country/organization identified by their individual user name and password. 
 Free of Charge  
The UMC has available a version of VigiFlow with limited access, which is free of charge 
to member countries with limited resource. For this free version the functionality not 
available includes the E2B import and export and the search and statistics module. This 
version is primarily meant to be used for sending ICSRs to the UMC. 
3. Feedback to the reports 
After insertion of the report in the VigiFlow, is always sent a confirmation of receipt of the 
reporting to the reporter. The letter of feedback consists in a summary of the case, the 
identification number in the database and the causality attributed.  
3.1.2.1 Risk Management and Communication 
Due to its characteristic the SRS are the easiest to establish and the cheapest to run and 
have proven their value in identifying uncommon or unexpected ADRs and creating 
hypotheses to be tested in subsequent studies. Nevertheless, low and irregular 
spontaneous reporting rates greatly limit the advantages offered by this surveillance 
method, so it is difficult to determine the actual number of individuals experiencing an 
adverse reaction. So with this uncertainty and lack of information on the number of 
patients exposed to the drug in question, it is not possible to accurately estimate the rate 
and frequency of ADRs through spontaneous reporting. Furthermore, it is estimated that 
only 10% of all reported adverse reactions are reported(42, 49).  
The identification and evaluation of signals constitute one of the main objectives of 
pharmacovigilance, and a signal is generally understood as “reported information on a 
possible causal relationship between an adverse event and a drug, the relationship being 
unknown or incompletely documented previously”(49). Generally it requires more than one 
report do generate a signal, depending on the seriousness of the event and the quality of 
information. The signals can arise through the SRS, prescription event monitoring, case 
controlled surveillance, record linkages, clinical trials databases and registries. Recent 
additions to these sources include large comprehensive population databases, such as 
electronic health-care records and health insurance systems. 
In Cape Verde the SRS rely heavily on the spontaneous report. So, despite the annual 
number of notifications to be negative, the quality of reports sent by the reporters has 
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improved over those years. The quality of spontaneous reports is very important for the 
adequate assessment of the safety of medicine. For example, in 2010, total report 
received was 16, but only 8 reports had sufficient information to allow a proper analysis of 
the case and its inclusion in the database (Figure 7). The health professionals, especially 
pharmacists are those who most have reported over the years. The national distributor 
and producer or the MAHs do not report ADRs to the agency, despite the existence of the 
legal enforcement. Furthermore, local operators (industry and distributor) have no 
pharmacovigilance procedures installed. 
 
Figure 7: Evolution of the Reporting of ADRs and quality problem 
 
Thus, considering that the primary function of pharmacovigilance is to provide early alerts 
of unknown or previously incompletely documented ADRs ("Signs"), and the number of 
reports received so far, the generation of signal with SRS is almost nonexistent in Cape 
Verde.  
Regarding the risk management, what I did during the internship, and is the current 
practice of ARFA, was daily visit the web site of medicines regulatory agencies of 
countries where medicines are most imported, namely the Infarmed website (Portugal), 
the ANVISA website (Brazil) and the European agency of medicine (EMA) website and 
search for any safety measure taken in respect to those medicines Figure 8  
The safety information from external sources was used to enact regulatory measures. I 
was responsible for preparing any safety alert towards medicines available in the country, 
and send them to all health professionals in pharmacy, hospital, health center and private 
clinic. To quality problems with a specific batch, the alert is sent first to the national 
importer (EMPROFAC) to verify the existence of that specific batch and whether the batch 
is available, the alert is sent to hospital, pharmacies, health center and private clinic to 
proceed to the recalls. 
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Figure 8: Safety measure cycle 
 
For medicines produced locally, any external alert regarding the pharmacotherapeutic 
class that those medicines belongs are sent to the health professional, with the 
identification of those medicine produced locally. Annually the ARFA collect randomly 
samples of medicines available in the country, both imported and locally produce, and 
sent to the INFARMED to perform the laboratory analysis. Depending upon the results 
safety alert can be sent to the pharmacies, hospital, health centre and private clinic, in 
case of the medicine is already available in the market.   
 
3.1.3 Educational Interventions on Pharmacovigilance 
SRS is the most widely used method in the ADRs reporting, which is enables to early 
detect new, rare and serious ADRs. Spontaneous reports are generated during routine 
diagnostic appraisal of the patients by the health professional. However, substantial 
under-reporting exists and is the major obstacle for rapid and relevant signal detection of 
new and/or serious ADRs. Moreover knowledge, attitude, and practice regarding ADRs 
reporting has been studied extensively, and in general, lack of knowledge about ADRs 
and attitudes to ADRs are the major cause of under-reporting. 
Improving reporting rates of ADRs is primarily about improving awareness of the need to 
report and the mechanisms used to submit the reporting form. Thus the degree to which 
health professional are informed about the principles of pharmacovigilance, and practice 
according to them, has a large impact on health care quality. Education and training of 
health professionals in medicine safety, by linking clinical experience of medicine safety 
with research and health policy, all serve to enhance effective patient care. Thus, the 
Website of Countries where 
medicines are most imported 
     ARFA 
National Industry and 
Importer 
Health Institutions 
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dissemination of pharmacovigilance to healthcare professional and patients is paramount 
to improve the quality, safety and efficacy of medicines available.  
However in the case of Cape Verde it cannot be talked now about the “underreporting” 
given that legally the system does not exist, and what can only be done is to sensitize the 
healthcare professional to this new concept and obligation in relation to the patient’s 
safety and the improvement of the health care delivered.  
In relation to educational intervention the main activity performed during the training 
comprised: 
 The preparation and training of healthcare professional of health structures, such 
pharmacies, hospitals and health centre for the importance of pharmacovigilance 
in improving patient’s safety; 
Adverse reactions tend to be viewed, incorrectly, as “side effects” and thus are distracted 
from patients and doctors priorities, thus learning about the scope and severity of ADRs 
should start early in professional training. Moreover, good safety monitoring encourages 
health professionals to take fuller responsibility for the medicines they use. This improves 
clinical effectiveness and increases the confidence with which they and their patients use 
medicines.  
Health professionals are more likely to identify and report important ADRs, if they have 
confidence in their ability to diagnose manage and prevent such reactions. National 
pharmacovigilance centres and training institutions play a central role in this by 
encouraging inclusion of the principles and methods of pharmacovigilance and the study 
of iatrogenic disease in the clinical practice and educational institutions.  
The intended result of this training is to educate the health professionals in the area of 
ADRs /quality problems, and sensitizes them to the identification and reporting of any 
problem with medicines. Moreover, the construction of a surveillance system, supported 
by an information system, which allows the implementation of a comprehensive model of 
pharmacovigilance that allows timely the collection of reports of suspected ADRs and 
other problems related to medicines, their assessment, management and communication 
of risk, are of vital importance to the improvement of the quality of care delivery.  
I was responsible to prepare the educational material and the training visit to the health 
centres and hospitals (Appendix 2). The training programs lasted about an hour and have 
as syllabus the: 
 Worldwide importance of Pharmacovigilance; 
 Methods used in Pharmacovigilance; 
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 National Pharmacovigilance System; 
 Spontaneous Report System: The report form and other forms of reporting 
 Case Studies in Pharmacovigilance 
The program comprised primarily the north region of Santiago Island (Sta Catarina – 
health centre and the regional hospital, S. Miguel, S. Salvador do Mundo, Tarrafal, S. 
Lorenço dos orgãos). At the end of this educational program, approximately hundred 
eighty six health professional (understood as persons authorized to prescribe, dispense 
and administer medicines) were trained in how to report, what to report and with what 
urgency to report ADRs or quality problem to ARFA.  
During this training session, the health professionals were distributed a simple 
questionnaire, which had as the general aims assess the knowledge of health 
professionals about issues relating to pharmacovigilance in Cape Verde in order to create 
a pharmacovigilance system efficient and adjusted to the current reality. The specific 
objectives of this questionnaire were to identify the causes of non-reporting and assess 
the percentage of health professionals who have already reported.  
The questionnaire consisted into a theoretical and a practical part (see Appendix 3). The 
theoretical part consisted of questions about the definition of pharmacovigilance and its 
main purpose, as well about the knowledge of the existence of pharmacovigilance system 
in Cape Verde. The practical part consisted essentially in questions about the health 
professional attiudues before an ADR’s, mainly the reasons for non-reporting. The 
question was constructed from a literature search of similar questionnaires (50, 51).  
From a universe of hundred eighty (186) healthcare professional that assisted the training, 
ninety night (99) answered the questionnaire. The average age of the respondents was 
37.72 years, being mostly females. Regarding the professional classes, about 28.3% of 
the respondents were nurses, 18.5% general practioners, 17.2% other health 
professionals (sanitary agent, psychologists), 15.2% technical assistants of pharmacy, 
14.1% medical specialists and 6.5% pharmacists. 
The analysis of the questionnaire indicated that only 20% of the respondents have already 
reported a ADRs or quality problems with medicine and that only 45% of the respondents 
known what pharmacovigilance is and its purpose. In addition, 35% of the respondents 
known about the existence of the reporting form and pharmacovigilance system in Cape 
Verde. In terms of main cause for non-reporting, lack of time (31.9%), indifference (31,9%) 
and financial incentives (29,8%) were the main reasons appointed by the respondents. 
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However, despite this preliminary conclusion achieved, it is important to highlight some 
shortcomings of this questionnaire. These shortcomings include, for example, the sample 
collected, which was a convenience sample, i.e, the sample was governed by the 
availability of the health professionals that attended to the training session, so the 
resulting sample is not representative of the general population. This method is a non-
random sampling method, pragmatic and intuitive character.  In terms of the questionnaire 
design it is important to stand out that there was no validation in relation to linguistic or 
interpretative issue and that no pilot study to assess the questionnaire’s reproducibility 
were conducted.  
 
 The preparation and distribution of weekly pharmacovigilance newspaper 
One of the important strategies for integrating pharmacovigilance into clinical practice is to 
create open lines of communication and broader collaboration between health 
professionals and National Centre. For this to happen, the national pharmacovigilance 
centre needs to be situated in a two-way communication between health professional and 
the centre. 
During the internship I was responsible to develop and implement this activity, which 
consists in the elaboration of pharmacovigilance bulletin. This newspaper is sent to the 
health professional in pharmacies, hospitals, health centre and private clinic. The main 
objective is to inform the health professional and encourage them to be more aware about 
the events that can appear with the use of medicines, and the significance of those events 
on the patient’s safety and care provided. Each week the newspaper shows a different 
perspective of prescription, administration and dispense of medicine, both in relation to a 
specific medicine as in relation to a pharmacotherapeutic class. Example of this bulletin 
can be found in Appendix 4. 
 
3.1.4 ADRs in Hospital Setting: Prospective Observational Cohort Studies  
The main activity performed in relation to this study was to collaborate in the critical 
analysis of the project, the discussion of the sample sizing, the criteria to establish the 
suspected cases, the causality algorithm and the proposal of a formulary to collect data.  
ADRs are encountered in as many as 10-20% of hospitalized patients and lead to 3–7% 
of all medical admissions(13). Drug-induced morbidity leads to increased suffering, 
prolongs hospital stay and causes a significant increase in hospital expenditure. Besides, 
aware that hospitals constitute an important element of post-marketing surveillance since 
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they concentrate cases of ADRs as a cause of hospitalization or its prolongation, it was 
proposed a study to obtain data, once non-existent, of the impact of ADRs in health 
service in Cape Verde.  
The objectives of this project is to (1) initiate a process towards a reporting culture, raising 
awareness and encouraging health professionals to report, (2) obtain data on ADR’s and 
quality problems occurring in the country and to characterize them and (3) to obtain 
comparison data between the intensive monitoring methodology and spontaneous report. 
Thus, considering the lack of data of this nature in Cape Verde, the methodology 
proposed involve a comparative analysis of the data collected in the two central hospitals 
using different methodologies for reports collection: the hospital Agostinho Neto (Praia, 
Sotavento region) and the hospital Baptista de Sousa (Mindelo, Barlavento region). The 
intensive monitoring methodology will be used in Agostinho Neto Hospital after a pilot 
study in the Hospital Santa Rita Vieira to assess the sample size and testing of tools for 
information collection. A comparison will be made with data from spontaneous reports 
received from the same hospital and with the Hospital Baptista de Sousa. 
Adverse drug reactions will be identified through intensive chart review, which is 
recognized as the gold standard for obtaining data on the incidence of ADRs(52). This 
intensive monitoring methodology will be used in the hospital Agostinho Neto and involves 
collection of information from medical records/ therapeutic records of suspected adverse 
reactions during the period required to identify the results. This study includes hospitalized 
patients in the two hospitals during the indicated period and excludes inpatient less than 
24h. Thus, given the lack of previous studies, the sample size calculation will be done as 
a simple random sampling followed by stratification per service, and after the encryption 
the files will be randomly chosen.  
The data that will be collected includes: patient demographics (age, gender), medication 
data (dosage, route of administration, frequency, start and end date of each prescription) 
and admission diagnosis. Data will be collected in a standardized format, for example, for 
prescribed medicines each chemical compound or combination compound according to 
the Anatomic Therapeutic Chemical (ATC) classification was considered, and for 
diagnose of disease the International Classification of Diseases version 10 (ICD10).  
For each hospital involved, and if approved by the National Ethics Committee for Health 
Research (CNEPS), the protocol provides the: 
 Presentation of the study to the Director for approval; 
 Team-Composition with hospital staff to be appointed for that purpose; 
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 Development of protocols for confidentiality;  
 Establish procedures and timeline for data collection; 
 Training on pharmacovigilance: sessions on the importance of reporting in 
hospitals; 
 Presentation of preliminary data by the researcher; 
The investigator is required to guarantee the anonymity of patients referred in medical 
records, as well the confidentiality of all data. 
Currently, the project has been already submitted to the CNEPS and the administrative 
board of the respective hospitals. 
 
3.1.5 Risk Management Plan  
The recognition that information about medicine safety is limited at the time of 
authorization only contributes to reinforce the need to implement measures to minimize 
identified and unidentified risk arising from the use of the medicines. Therefore, monitoring 
of medicines in the post-marketing is a tool of utmost importance to ensure the quality, 
efficacy and safety of consumers, thus helping to safeguard the public health. Moreover, 
as described in the report of the WHO World Alliance for Patient Safety, the skill and 
ability of programs to improve patient safety, depends on its ability to aggregate the most 
complete information on ADRs, so that they serve as a source of knowledge and basis for 
future preventive actions. The planning of pharmacovigilance activities necessary to 
characterize the safety profile of a medicines will only be improved if it is heavily based on 
the specific issues identified from the data generated during the pre-and post-market or 
based on pharmacological principles. The purpose of the identification and 
characterization of risk is to allow its minimization or mitigation whenever possible(53). 
So, considering the news competences recently transferred to ARFA, which included the 
management of the medicines authorization system, I was proposed to develop a draft of 
the risk management plan (RMP).  
The draft of the RMP developed aims to provide practical guidance for the preparation 
and elaboration of the RMP by the MAH or his representative, present in the national 
market. One of the legal requirements proposed is that the RMP should be submitted with 
the application for marketing authorization, without prejudice to be prompted for an update 
whenever there is a concern about a risk that could affect the risk-benefit ratio of the 
 36 
 
medicine. The RMP should be submitted to all medicines, although in generic medicines, 
it is not necessary to include the clinical data.  
The RMP consists of 6 modules, which are subdivided into parts, which include the 
summary of the product, the safety specification, pharmacovigilance plan, risk 
minimization plan, the references and the annexes. The general summary of the product 
provide the administrative information of the RMP, and a summary of general information 
(s) of product (s) that this plan covers. The safety specifications provide a synopsis of the 
safety profile of the product (s) and include(s) what is known or unknown about the 
product(s). Any security considerations should be discussed in this module as they 
constitute potential risks. The pharmacovigilance plan details the activities/studies which 
are intended to identify and/or characterize the safety concerns identified in safety 
specifications of the product (s). The risk minimization plan (RMP) must provide details of 
the measures to be undertaken to reduce the risks associated with a particular safety 
concern. The Annex will include the SPC, patient leaflet, the authorization status at a 
global level, as well as study programs or other relevant information. 
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3.2 Multidisciplinary Activity  
During my internship I participated in other activities outside the main scope of my 
internship. Besides, one  of  the  objectives  of  the  internship  was  also to  acquire  
multidisciplinary  knowledge  and  experience. I performed several activities within the 
following area: 
 Medicines Registration and Price Fixing 
 Inspections to market operators 
 
3.2.1 Medicines Registration and Price Fixing  
During the internship I was responsible to register and calculate the price for over a 
thousand of medicines.  
Under the NPP approved by Resolution n.º 16/2003, of 28 July, in which are absorbed the 
WHO guidelines, Cape Verde has recognized as priority issues for action in the 
pharmaceutical sector, the regulation of price of medicines and health products, the 
accessibility to quality medicines and the need for a monitoring system covering the 
pharmaceutical market. The priority in this regard is reinforced with the provisions of DL  
n. º 22/2009  and the DL n. º 64/2009  which establishes the legal regime to be met the 
criteria for pricing of medicines and establishes the SIMFAR(54). 
The SIMFAR is a means of implementing the guidelines of the NPP, which aims to 
facilitate and /or ensure accessibility, by balancing the availability and the price, the quality 
of the medicinal product, the safety and effectiveness and rational use of medicines. The 
organizational structure of SIMFAR is based on technical and economic regulation, and 
includes: 
 Marketing authorization  
 Maximum price /prices monitoring and stocks; 
 Post-marketing surveillance system (quality/safety). 
This system provides the registration of all market operators. The registrations are made 
by completing of an electronic form. Furthermore, the manufacturer or importer must 
submit to ARFA an application for price approval, to which is assigned a unique medicine 
code to an unequivocal identification in the Cape Verdean market. The code is randomly 
assigned by the system and is related to a set of minimum information requirements. 
Currently, the marketing authorization system is not working, and there are thousands of 
medicines available in the country that are not registered and do not have an 
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authorization. Thus, since this register system is not working as was provided, the ARFA 
is now requesting to the EMPROFAC information about those medicines, in order to 
register them in the SIMFAR's database.   
During the registering of medicines, if the INN belongs to the NML in the same 
pharmaceutical form and dosage, it is attributed in the registering process the 
reimbursement echelon. 
In Cape Verde, the reimbursement system is defined according to the beneficiaries, and 
there are essentially two regimes: the general and the special(55).  
 General regime: For insured and their families the following echelon are applied: 
echelon A (85%), echelon B (75%), echelon C (55%) and echelon D (50%). Yet in the 
general regime are included pensioners and their families. This category includes only 
pensioners receiving pension equal to or greater than two and half times the national 
minimum wage (approximately 100€). For these beneficiaries the echelon to be 
applied is: echelon A (95%), echelon B (85%), echelon C (60%) and echelon D (55%). 
 Special regime: This category includes pensioners and their families. This includes 
only pensioners receiving pension less than or equal to two and half times the national 
minimum wage. For these beneficiaries the medicines are 100 percent reimbursed.  
 
Regarding the price, the ARFA is responsible for: a) approve the provisional prices and 
maximum prices of medicines covered by this regime b) authorize ordinary revisions, 
adjustments and extraordinary revisions and c) monitor and supervise its compliance.  
In Cape Verde are subject to the pricing scheme all medicines in the country, except over-
the-counter medicines, herbal remedies, homeopathic, handled or officinal prepared and 
veterinary medicines. The medicines excluded from the pricing system are, however, 
subject to the procedures provided for monitoring and regulation to be prepared by ARFA. 
To the maximum price approved by ARFA is allowed to practice discounts throughout the 
medicine circuit, from the manufacturer to the pharmacy or to the consumer, since that 
safeguarded the quality of medicines, in particular as regards to shelf life. Moreover, the 
deductions made by pharmacies in reimbursed medicines by the INPS can focus 
exclusively on the part of the price not reimbursed. 
For the purpose of pricing, medicines are classified in the following categories(35):  
a) Category I: new medicines with therapeutic gain; new dosage forms of existing 
medicines in the market and new dosages involving new indication with 
therapeutic gain. 
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b) Category II: new medicines without therapeutic gain and new dosage forms of this 
medication; 
c) Category III: medicines whose active substance already exists in the country, as 
well as new strengths and new presentations of existing medicines that do not 
involving new indication or therapeutic gain; 
d) Category IV: generics medicines; 
e) Category V: medicines used strictly in hospitals; 
Medicines that cannot be fit into the above categories are provisionally classified in 
category II until completion of the revaluation and the subsequent classification in 
definitive category. Clinical data and other that demonstrate the existence of therapeutic 
gain in accordance with the guidelines established by the WHO are used in the final 
definition of the categories.  
The prices of medicines sold in pharmacies are constituted by the Maximum Price to 
Pharmacy (MPP), and the Maximum Price to the consumer (MPC). The methodology 
used in calculating the MPP is based on comparison of the average of selling price to the 
wholesaler (SPW) of medicines identical or essentially similar in the countries set as 
reference, with the subsequent addition of marketing margin. The reference countries to 
be used in price comparison are Spain and Portugal. 
For purposes of comparison the following criteria are considered in accordance with the 
following order of priority: 
a) With the same pharmaceutical form, dosage and presentation; 
b) With the same pharmaceutical form, dosage and closer presentation; 
The MPP is determined based on the comparison between the prices of the nearest 
presentations in each reference countries. Where the difference between presentations 
and one whose price should be calculated is equidistant, is chosen the largest 
presentation. The criterion "presentation" for purposes of pricing applies up to three times 
the packaging of the medicines concerned. Whenever the package in question is more 
than three times the comparable medicine packaging, the pricing is determined by the 
administrative board of ARFA. 
Thus, after comparison of the mean of SPW of medicines identical or essentially similar in 
the countries set as reference is added the corresponding margin, depending on the 
category in which the medicine is included. The marketing margin for the wholesaler to be 
used for purposes of determining the MPP for medicines included in categories I, II and III, 
and the medicines included in category IV, which the reference product is not sold in the 
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country is 24 percent for the lowest average of the SPW. For generic medicines with 
reference medicines1 available in the country, the MPP should be 20 percent less than the 
reference medicine. The methodology used in calculating the maximum price of hospital 
medicines, enrolled in category V, is based on the comparison of the averages prices in 
reference countries, and the subsequent addition of the marketing margin of 15 percent. 
The marketing margin of pharmacies and medicine sales points to be used for the 
purpose of MPC determination is: 
a) 30 percent of the MPP for medicines in category I, II and III;´ 
b) 37.5 percent of the MPP for medicines in category IV; 
For situation where the medicine is not being marketed in at least one of the reference 
countries, or the price was not found in the country of origin, and proven the urgency in 
terms of public health interest, the administrative Board of ARFA, heard the opinion of the 
Chairman of the National Medicines Commission, can fixing a provisional price until there 
are the conditions provided. 
In Cape Verde, the prices of medicines are subject to annual review and adjustment 
prices, without prejudice to be made an especial review at any time, as determined by the 
Administrative Board of ARFA. Additionally, the manufacturer or importer can request for 
price adjustment. 
To monitor the implementation of the price determined, the manufacturers, importers, 
distributors, wholesalers and pharmacies are required to submit to ARFA, each month, the 
data relating to the medicine marketing in respect to the previous month. Currently this 
requirement is fulfilled only by few of operators. 
This methodology of price fixing is currently under revision, due to practical shortcomings, 
for example, there is a limited evaluation of the therapeutic gain of medicines, and the 
category II are seldom applied, due to limited information. Furthermore, the category IV is 
very broad to apply since all other medicine included in other category can have generic 
medicines. This category can only be applied for the first generic medicine that does not 
present any therapeutic gain. In addition, the sources of information on the price of 
imported medicines are very limited and insufficient.  
 
                                               
1
 For the purposes of price fixing, the reference medicine is defined as the first medicine marketed 
in the country whose active substance has been authorized on the basis of full documentation. 
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3.2.2 Inspection  
During the internship I was responsible to update the inspection checklist, the register 
form and prepare the inspection report (Appendix 5).  
Routine Inspection   
With the health sector reform, private pharmacies have become an important source of 
health care, frequently functioning as a first-line care. Thus, considering the 
representativeness of the private pharmacy, particularly in developing countries, and the 
fact that private provision of medicines has been associated with risks regarding 
availability, affordability, rational use and drug quality, he guarantee of an effective 
regulatory framework and permanent monitoring becomes therefore essential to ensure a 
balance between affordability and quality(56, 57). 
In Cape Verde, the DL nº 34/2007 regulates the conditions of access to pharmaceutical 
activity and exercise in pharmacy. According to this DL the opening of a new pharmacy is 
preceded by a public tender, and the pharmacy can only open to the public after the 
attribution of the license by DGFM. The tender is open by order of the DGFM, whenever 
there are reasons for pharmaceutical coverage and heard the health center of the 
installation area, the ARFA and the consumers association, having jurisdiction in that 
county. The owner of a pharmacy can be individuals or commercial companies(58). 
The pharmacy and medicine sale points are the only local authorized to sale medicines in 
Cape Verde. Moreover, the pharmacies can only supply medicines to the public present in 
NML and whose import has been specifically authorized. However, within the NML there 
are some medicines that the medicine sale point cannot sale, due to its characteristics. 
The inspection activity is conducted in the scope of the annual visit to the operators of the 
pharmaceutical sector, called SIMFAR mission. The main objectives of the mission are to 
collect and update data from operators, to raise awareness among pharmacy 
professionals for the identification and reporting of suspected ADRs and quality problems, 
as well as verification of compliance in relation to the minimum requirements established 
by law. The expected result is to have professionals informed and aware about 
pharmacovigilance, as well as for the monitoring of aspects related to price, stock and 
medicines distribution. 
The inspection consisted essential three phase: 
 The update of the operator register 
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This consisted basically in collect general information about the pharmacy such the 
technical director, the address and contact, as well, listen constraints that pharmacies 
have been in relation to the EMPROFAC or other health structure.  
 The sensitization of the importance of pharmacovigilance 
This sensitization consisted essential in an introduction of what is pharmacovigilance, its 
importance in the improving of the quality of life of patients and health care. The 
sensitization also focused in what to report, how to report, and the urgency to report a 
suspected ADR and quality problem.  
 The conformity verification; 
The conformity assessment was conducted according to the decree-law 31/2007 which 
regulates the functioning of pharmacies, including requirements to be met by the facility 
pharmacies and medicine sales points.  
The aspect checked during the visit was(59): 
 Signalling: consist in verify if the word "Pharmacy" is correctly signed to the public, 
as well as information about operating period, the name of the technical director 
and the on-duty pharmacy. 
 Documentation: according to the present DL a pharmacy should have a 
compilation of the main laws of the pharmaceuticals sector, as well as the license 
certificate available to the competent authorities.  
 Facilities: the legislation also provides that pharmacies must have a minimum 
useful area of 80m², and it is also compulsory the existences of the following 
divisions: the area of public attendance, storage area, office, laboratory and /or 
attachment, toilet facilities and a ventilated area that allows to rest during the duty 
shift. 
 Conditions of the divisions: according with the legislation in force the pharmacies 
should be kept in a permanent state of cleanliness and hygiene. For example, the 
medicine should be in places clean and fresh, not exposed to direct sunlight; 
properly arranged on the shelves, glazing cabinets, and away from the contact 
with the wall. 
 Personals: The pharmacies should have at least the following personal: a technical 
director, and a technician pharmacy assistant. In addition, all workers should have 
the pharmacy bulletin of sanity updated, and should use white coats during the 
working period. 
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Following inspection, the pharmacies receive the inspection reports, which include the 
summary of the non-conformity found, as well as the corrective measures to be 
implemented. At the end of the internship I visited approximately 10 pharmacies. 
Nevertheless, despite all the provisions, the applicable legislation is not  being fully 
implemented, because due to the ineffectiveness of the medicine authorization system, 
the NML is not followed, and currently the pharmacies sold several medicines that were 
not authorized to be in the country and do not belong to the NML.  
 
Inspection by anonymous tips 
The involvement of the population in the pursuit of their right in have access to safe, 
effectives and quality medicines represent an add value in the medicine monitoring 
system. Thus, the improvement in the health service depends on the involvement of the 
whole community. In this line, often come to ARFA anonymous complaints that some 
unauthorized store is selling medicines. When those complaints comes to ARFA it is 
immediately initiated an inspection procedures. 
During the internship, I had the opportunity to participate in an inspection to a Brazilian 
store that sold various herbal medicines, banned since 2005 in Brazil by ANVISA. Those 
medicines included: Agonida, Depuratone, Acachofra Milian, Biotónico Fontoura, 
Composto para Varizes, Reumat Ervas, Ervas Vida, Tóniocardio, Saúde do Homem, 
Extrato concentrado Unha de gato, Glicos Ervas, Mulher Sempre Saudável e Relax 
Ervas. It matter to highlight that in Cape Verde, regardless the type of medicines, for 
example OTC, herbal medicines, generic drug and innovator, the pharmacy and in drug 
sale point duly authorized are the only place authorized to sale medicines.  
This has led to the instruction of an administrative offense, and in accordance with DL nº 
34/2007 the sale of medicines in unauthorized stores constitutes offense punishable with 
a fine of € 50 and €1000 or €1500 and €3000 depending on whether the offender is a 
person or legal person. 
Despite the evidence of growth of illegal market sale of medicines, the inspective capacity 
of ARFA is limited, and often the most seizures with medications in stores are made by 
the General Inspectorate of Economic Activities (IGAE). 
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4. Discussion  
This chapter discusses the main gains achieved during this internship, the main difficulties 
encountered, as well as the general limitation of pharmacovigilance in Cape Verde. 
Once this internship was held at the NMRA, it gave me the chance to understand how 
pharmaceutical sector in Cape Verde is organized and how marketing control and 
surveillance are performed in low-income country, such as the case of Cape Verde. 
Furthermore, since the pharmacovigilance is being installed, I had the opportunity to 
evaluate and comment the draft law for the creation of the national pharmacovigilance 
system.   
During the internship it was not easy for me to realize that despite the global environment 
of increasing demands in terms of medicines safety, efficacy and quality, there are 
countries that have a poor control of the medicines available. For example, given that the 
medicine authorization system was not working, the ARFA often unknown what types and 
what medicines were available in the market. 
One of the main difficulties encountered during this internship was the knowledge and 
availability of major legislation of the pharmaceutical sector, and the existence of 
overlapping competences between public entities. Nevertheless, I really appreciated the 
fact that I was entrusted with the responsibility of managing the pharmacovigilance of 
medicines through the promotion of new activities for this area. I was responsible to create 
and manage the pharmacovigilance bulletin, which aims to inform health professional 
about some pertinent issues of their clinical practice.  
In Cape Verde, despite the remarkable progress in health indicators that the country 
reached, the current epidemiological transition, import dependence, the fragility of the 
authorization system of medicinal products, and evidence of growth of illegal market of 
medicines, are factors that evidences a need to strengthening the surveillance system. 
Thus, regarding the current pharmacovigilance practice, the main constraints are similar 
with the most African countries and can be broadly divided in: 
 Policy, Law, and Regulation 
Despite the DL that regulate the medicine authorization system have legal provisions that 
require MAHs, physicians, technical directors of pharmacies or other health professional 
to report all serious ADRs to the NMRA, this engagement is very limited. Thus, to address 
the inexistence of a national policy related to pharmacovigilance and medicine safety, 
there is a proposal currently under revision for being approved that establishes the NPS, 
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and consequently the MAH obligations in relation to each medicine available in the 
country. 
 Signal Generation and Data Management 
The scope of pharmacovigilance is limited in most of the African countries, and Cape 
Verde is no exception. Although there is a SRS in Cape Verde, the system mainly 
consists in data gathering. The pharmacovigilance database prospected is not currently in 
use due to some operational shortcomings and the reports are entered into the Vigiflow 
database.  
 Risk Assessment and Evaluation 
The reporting rate is minimal and generally less than 20 reports per million populations 
per year. Besides, the capacity to conduct medicine safety research exists, however yet 
active approaches to identify and evaluate medicine-related risks are limited. The 
incorporation of active surveillance activities into the NPS represent a viable alternative to 
improve the number of reports. Additionally, I have proposed a list of stimulus measures 
that can be adopted to increase the number of reports.  
 Risk Management and Communication 
It Cape Verde it is used the safety information from external sources (from other NMRA) 
to enact regulatory measures, although sporadically, which are sent to the health 
professional in form of alert or newsletter. Moreover, there are no procedures for 
managing or minimization of important known harmful effects of high-risk medicines. 
There is no formal requirement for risk management activity to prevent or minimize 
problems related to the medicine. To address this scenario, the ARFA should develop a 
framework, tools, and guidance documents for comprehensive risk management practices 
tailored to the current context. During the internship I was required to develop a proposal 
of the risk minimization and management plan for medicines of human use. 
This scenario evidences that greater efforts are needed to build the pharmacovigilance 
system and to link existing activities to create a comprehensive pharmacovigilance 
system. The ARFA should develop strategic plans to incorporate both passive and active 
approaches, coordinate and work with all stakeholders, strengthen risk management and 
communication, and enhance the impact of pharmacovigilance and medicine safety 
systems. The successful execution of these plans will improve patient safety and health 
outcomes. 
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5. Conclusion  
The 9-month experience earned during this internship was a unique experience, where I 
could put into practice the knowledge gained during the academic training which allowed 
me to provide pertinent contribution to ARFA. Besides, because of my multidisciplinary 
view and knowledge of the pharmaceutical European legislation, gained during the 
course, it makes me a great source of information and communication within the ARFA. 
Nevertheless, I would like to highlight that several changes are taking place in the 
complex system of drug development, regulation and distribution, and the access to new 
essential medicines, such as artemisinin-based combination therapy and antiretroviral 
therapy in Africa, creates a greater need to monitor and promote safety and effectiveness 
of medicines. So, pharmacovigilance should be more proactive in monitoring their 
possible consequences. 
To the Cape Verde pharmacovigilance system the strategic plan should go through 
efficient and timely identification, collection, assessment, and communication of medicine-
related adverse events. Being in light that, a comprehensive system includes both active 
and passive surveillance methods, effective mechanisms to communicate medicine safety 
information to health care professionals and the public, collaboration among a wide range 
of partners and organizations, and incorporation of pharmacovigilance activities into the 
various levels of the health system. 
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Appendix 1: Proposal for the New reporting Form and the 
Abbreviated Form 
CONFIDENCIAL
Notificação nº:________
Os campos assinalados com (*) são de preenchimento obrigatório
1. *Identificação do doente
Data de nascimento ou idade _________________
Peso:___________Kg Altura:_________cm
___/___/___
___/___/___
    A dose do medicamento foi aumentada Sim     Não   Não sabe
Lote Posologia Forma Farmacêutica Inicio de uso
___/___/___
___/___/___
__/___/____
__/___/____
Sim Não
    Resultou em incapacidade 
    Provocou anomalias congénitas
    Outro: ____________________
    Em Recuperação 
             Contatos: 
Razão de uso
     Motivou/Prolongou a Hospitalização
Foi necessário efectuar algum tratamento da reação adversa?
___/___/____
Se sim, porque considera grave?
Considera a(s) reação adversa (s)  grave?
Obrigado pela sua colaboração!
Duração se a Reação for 
inferior a 1 dia
    O medicamento foi suspenso devido à reação 
Tel: _______________________
4. *Descrição da Reação adversa  
Problemas  de qualidade relacionados com Medicamentos
    Não     Sim Qual?_______________________________________
5. Tratamento/Evolução da Reação Adversa
    Recuperou, data____/____/_______ 
CENTRO NACIONAL DE FARMACOVIGILÂNCIA
     Desconhecido
___h____min
____/___/___
___/___/____
2. *Produto Suspeito (se suspeita de interacção medicamentosa, considere os respectivos medicamentos como suspeitos)
___/___/____
Nome 
(iniciais) 
Fim de uso
    A dose do medicamento foi diminuida
____/____/_____
___/___/_____
___/___/____
3. Medicamentos concomitantes (inclui também automedicação e utilização de outros produtos)
Medicamento   
___/___/_____
___/___/______
    Nada foi alterado
Que ação foi tomada?
____/____/_____
____/____/____
___/___/______
*Data de inicio 
___h____min
*Data de fim 
___h____min
___/___/______
Formulario de notificação de suspeitas de Reações Adversas/Problemas de 
Qualidade para Profissionais de Saùde
Suspeitas de Reações Adversas
*Medicamento 
(Nome comercial)
Lote Posologia
Forma 
Farmacêutica
Inicio de uso Razão de usoFim de uso
     Colocou a vida em risco
____/____/_____
No caso de ter suspenso a medicação, o medicamento 
foi reintroduzido?
   Sexo: F       M_________________
_
     Resultou em Morte
___h____min
*Descrição do Problema: 
Fabricante:_______________________
 *N° de Lote: _________________
Nome: ____________________________
Instituição: ________________________ Data: ____/____/______
Profissão: _________________
Email: ______________________________
6. Comentários (dados relevantes de história clínica, farmacológica, alergias e exames auxiliares de diagnóstico ou outros)
*Dados do Notificador (campo de preenchimento obrigatorio tanto para reações adversas/problemas de qualidade)
Sequelas: Não      Sim     Qual? ____________________________________      
*Medicamento (Nome comercial): ______________________________________
 Data de Validade do Medicamento: ____/____/_____
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The Abbreviated Form 
CENTRO NACIONAL DE FARMACOVIGILÂNCIA
Sexo: F      M Peso:___________Kg
 
Sim Não
    Não      Sim 
    Recuperou, data____/____/_____
Sequelas: Não      Sim     Qual? ____________________________________      
Email: __________________________________
Qual ?_____________________________________
      Em Recuperação          Desconhecido
Notificação nº:___________
Não esqueça que ao preencher este formulário abreviado compromete-se a 
disponibilizar mais informações à ARFA. 
Obrigado pela sua colaboração!
E. *Dados do Notificador
Nome: ____________________________ Tel: _________________
Categoria Profissional:     Médico       Dentista      Farmacêutico      Enfermeiro 
Instituição: 
Assinatura: 
Os campos assinalados com (*) são de preenchimento obrigatório
Inicio de 
uso
Fim de uso
C. *Descrição da Reação adversa (RA) Data de fim
Duração se  
for ≤ 1 dia
Razão de uso
Forma 
Farmacêutica
Nome 
(iniciais) 
B. *Medicamento Suspeito (se suspeita de interacção medicamentosa, considere os 
respectivos medicamentos como suspeitos)
*Medicamento 
(Nome de Marca)
Data de inicio 
             Diminuição/aumento da dose
D. Evolução
Foi necessário efectuar algum tratamento da reação adversa?
Formulário Abreviado de Notificação de Suspeitas de Reações Adversas 
para Profissionais de Saúde
A. *Identificação do doente
Data de nascimento ou idade: _______________
Confidencial 
Considera a(s) reação adversa (s)  grave?
Posologia
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Appendix 2: Pharmacovigilance Presentation  
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Appendix 3: Questionnaire 
 
QUESTIONÁRIO SOBRE O SISTEMA DE FARMACOVIGILÂNCIA EM CABO VERDE 
Este questionário tem por objetivo avaliar o conhecimento dos profissionais de saúde sobre as 
questões relativas à farmacovigilância, de modo a criar um sistema de farmacovigilância 
eficiente e ajustado a realidade atual.  
 
Por favor Preencha os seus dados demográficos: 
Idade   Sexo:  M F   Qual a sua especialidade?______________________ 
Qual é o serviço onde exerce funções?____________________________________ 
Em que meio?  Hospitalar Centro de Saúde Clinicas Privadas Farmácias 
 
Instruções: Selecione com um círculo a opção correta para cada uma das seguintes 
questões 
1. Qual a definição de Farmacovigilância? 
a) Ciência que monitoriza a ocorrência de reações adversas medicamentosas nos 
hospitais  
b) Processo de melhoria da segurança dos medicamentos 
c) A ciência da deteção, avaliação, compreensão e prevenção dos efeitos adversos 
d) A ciência da deteção dos tipos e incidência de reações adversas após a 
comercialização do medicamento. 
 
2. O principal propósito da farmacovigilância é 
a) Identificar a segurança dos medicamentos 
b) Calcular a incidência das reações adversas medicamentosas  
c)  Identificar fatores de predisposição para as reações adversas medicamentosas  
d) Identificar reações adversas medicamentosas previamente desconhecidas 
 
3. O centro internacional de monitorização das reações adversas medicamentosas está 
localizada nos/na 
a) Estados Unidos da América 
b) Austrália  
c) França 
d) Suécia 
4. Tem conhecimento do sistema de notificações de suspeitas de reações adversas e 
problemas de qualidade em Cabo Verde?  
a) Sim  
b)  Não 
 
5. Em Cabo Verde qual é a entidade responsável pela monitorização de reações 
adversas e/ou problemas de qualidade a medicamentos? 
a) Direção Nacional de Saúde 
b) Serviço de Epidemiologia  
c) Direção Geral de Farmácia e do Medicamento (DGFM) 
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6. Identifiqueo (s) profissional (is) de saúde responsável pela notificação de reações adversas 
medicamentosas  
a) Médicos 
b) Farmacêuticos 
c) Enfermeiros 
d) Todos os indicados acima 
7. Conhece o formulário de notificação?  
a) Sim  
b) Não 
8. Em alguma ocasião, teve a intenção de notificar reações adversas medicamentosas e/ou 
problemas de qualidade e não dispunha do formulário? 
a) Sim   
b) Não 
9. Aconteceu-lhe alguma vez suspeitar de uma reação adversa a um medicamento mas não 
chegar a preencher o formulário, mesmo dispondo dela? 
a) Sim  
b) Não 
 
10. Alguma vez preencheu o formulário, que não chegou a enviar por causas distintas? 
a) Sim 
b) Não 
11. Já alguma vez notificou uma suspeitas de reacções adversas e/ou problemas de qualidade? 
a) Sim   
b) Não 
12. Quais de entre os seguintes fatores o (a) desencoraja de notificar suspeita de reações 
adversas/problemas de qualidade (escolha apenas uma) 
a) Falta de compensação económica para notificar 
b) Falta de tempo para notificar suspeita de reações adversas/problemas de qualidade  
c) Um único caso não notificado pode não afetar a base de dados de suspeita de reações 
adversas/problemas de qualidade  
 
13. Acha que a notificação de suspeita de reações adversas/problemas de qualidade é uma 
obrigação do profissional de saúde? 
a) Sim 
b) Não 
c) Não Sabe 
d) Talvez 
14. Já alguma vez leu algum artigo sobre a prevenção de reações adversas medicamentosas? 
a) Sim 
b) Não 
 
15. Jáalguma vezrecebeu formação em como notificar uma suspeita de reações adversas 
medicamentosas/problemas de qualidade? 
a) Sim 
b) Não 
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Appendix 4: The Pharmacovigilance Bulletin 
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Appendix 5: Inspection Materials 
 
 
 
 
 
 
 
 
Verificação de Conformidade(De acordo com a portaria 31/ 2007 de 15 de Outubro) 
Farmácia/PVM:                                                                                                                      Data:____/_____/___ 
 REQUISITOS Sim  Não  N/A 
1.  Sinalização  
 O nome da farmácia está devidamente assinalada ao público     
O nome do diretor técnico está visível no interior e exterior da farmácia     
O horário de funcionamento está de forma visível    
 A farmácia de serviço está afixada de forma visível    
2. Documentação 
 Certificado de alvará         
Compilação da Legislação farmacêutica      
Livro de registo da movimentação de estupefacientes e psicotrópicos       
Livro de reclamação e a sinalização da sua existência    
3. Área de atendimento ao Público 
 Os medicamentos encontram-se: 
a) Em lugares limpos e arejados    
b) Não expostos à luz direta do sol     
c) Devidamente arrumados nas prateleiras     
d) Armários envidraçados     
e) Afastados do contacto com a parede    
f) Existência de produtos estranhos à profissão farmacêutica    
Existência de armários com chave para estupefacientes e psicotrópicos    
4.  Área de Armazenamento 
 Recipientes destinados ao acondicionamento de medicamentos encontram-se: 
a) Ordenadas            
b) Rotuladas    
c) Limpas    
d) Não expostas ao público    
e) Afastados do contacto com a parede    
5.  Laboratório 
 O laboratório/anexo obedece ao estipulado pela lei (luz própria, janela, chaminé, 
paredes revestidas de azulejo, nicho para eliminação de fumo e gazes) 
   
Lavatório de louça vidrada ou de material inoxidável, pia e balde para recolha de 
água de lavagem dos pavimentos 
   
Mesas de trabalho conforme o estipulado na lei    
6. Mobiliário e equipamentos 
 Existência de frigorífico com termómetro     
Armário – vestuário fechado para arrecadação de pertences dos funcionários    
7. Condições de Higiene  
 Encontra-se em estado de asseio e higiene    
Possui água corrente    
Pessoal utiliza bata branca durante o funcionamento da farmácia    
Todas as divisões estão cimentadas ou ladrilhadas, os tetos estucados    
8. Pessoal 
 Diretor técnico    
Técnico ou auxiliar de farmácia    
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Inspector 1                                                                                                                              Inspector 2 
 
________________________                                                                                   ________________________                                                                                             
9. Área de Instalação Farmácia/PVM 
 Área de atendimento ao público    
Área de armazenamento    
Escritório    
Laboratório e/ou anexo    
Instalações sanitárias    
Área arejada que possibilite o descanso dos funcionários em serviço de turno    
OBSERVAÇÕES: 
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FICHA DE ATUALIZAÇÃO DE CADASTRO DE OPERADOR 
 
1.  Identificação da Farmácia/PVM 
 Nome: 
Endereço da sede: 
Telefone: 
Fax: 
Email: 
NIF: 
Nº de Licenças/Alvará: 
2. Identificação do Gerente 
 Nome: 
Contato: 
Email: 
Profissão: 
3. Identificação do Diretor Técnico 
 Nome: 
Contato: 
Email: 
Profissão: 
4.  Outros Funcionários (Nome/Profissão) 
 1. 
2. 
3. 
4. 
5.  Atividade 
 Data início de Atividade: 
Horário de Funcionamento: 
6. Informatização 
 Acesso a Internet: Sim  Não  
Nível de conhecimento Informático(Diretor/Gerente): Bom  Razoável  Mau  
7. Desenvolvimento das Atividades 
 Requisição:  
 a) Via fax  Email  Telefone  Outros: 
b) Periodicidade:  
c) Valor Médio por requisição: 
 Mercadoria: 
a) Período de Espera: 
b) Receção (ponto de levantamento): 
c) Procedimento de conferência da mercadoria:  
Transporte: 
 a) Via Terrestre  Marítima  Aérea  
 b) Custo médio do transporte:  
8.  Constrangimentos 
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RELATÓRIO DE VERIFICAÇÃO DE CONFORMIDADE  
 
Âmbito 
No âmbito das competências atribuídas à ARFA nos seus Estatutos e das grandes linhas 
de orientação da agência, foi concebido o Sistema Integrado de Monitorização do 
Mercado Farmacêutico (SIMFAR), cujo suporte legal e operacional permitem a recolha 
e tratamento de dados, sobre o fabrico, a importação, a distribuição, a comercialização 
e o consumo de medicamentos e produtos farmacêuticos. As informações recolhidas 
através deste sistema possibilitam realizar a monitorização do mercado farmacêutico, 
mais concretamente, no que respeita ao preço e stock, bem como a qualidade, 
segurança e eficácia dos medicamentos. 
Assim, tendo em linha de conta a necessidade de recolher toda a informação de 
carácter quantitativo e qualitativo que possa servir de suporte para a implementação 
das diferentes áreas do SIMFAR, a direcção de regulação farmacêutica da ARFA, no 
âmbito das actividades programadas para o ano de 2013, levou a cabo uma visitajunto 
aos operadores do sector farmacêutico.  
Objetivos 
A missão teve como principaisobjetivos a recolha e actualizaçãodos dados dos 
operadores, a sensibilizaçãodos profissionais para a identificação e notificação de 
suspeitas de reações adversas á medicamentos e problemas de qualidade, bem como a 
verificação de conformidade da farmácia em relação as condições mínimas exigidas 
por lei.  
Resultados Esperados  
O resultado esperado é o de ter profissionais informados e sensibilizados para as 
questões de farmacovigilância, bem como para a monitorização dos aspectos 
relacionados ao preço, stock e distribuição de medicamentos.  
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Relatório 
I - IDENTIFICAÇÃO DA FARMÁCIA/POSTO DE VENDA DE MEDICAMENTOS 
Nome: 
Endereço:  
Telefone: 
Email: 
Nº de Licença/Alvará: 
Número de profissionais do estabelecimento: 
Horário de funcionamento:       de      __________       ás      __________ horas 
Nome/Contatodo Diretor Técnico: 
 
 
Em anexo: Ficha de verificação de conformidade. 
II - CARACTERIZAÇÃO DA INSPEÇÃO 
Data: _____/_______/_____ Horário: ________________ 
Data da última inspecção:_____/_______/_____ 
i. Identificação das NãoConformidades 
 
 
 
 
 
 
 
ii. ContrangimentosApresentados 
 
 
 
 
III - CONSIDERAÇÕES 
 
 
 
 
 
 
 
IV - EQUIPA(Nome/Função) 
 
 
 
 
 
